RA0236

antibody from Oursmab

Targeting: EREG ER

Western blot (Data presented on provider website)

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0236

Provider

Oursmab

Product name

Fepixnebart (Biosimilar Reference Antibody) (EREG and TGFA)

Antibody type

Monoclonal

Description

Fepixnebart is an investigational, humanized immunoglobulin G4 (IgG4) monoclonal antibody being developed for the treatment of solid tumors. It functions as a dual-targeting ligand trap, specifically designed to bind with high affinity to two key ligands of the epidermal growth factor receptor (EGFR) pathway: epiregulin (EREG) and transforming growth factor-alpha (TGF¦Á). By neutralizing these ligands in the tumor microenvironment, fepixnebart prevents them from binding to and activating EGFR, thereby inhibiting the downstream oncogenic signaling cascades (such as RAS/MAPK and PI3K/AKT pathways) that drive tumor cell proliferation, survival, and metastasis. The IgG4 isotype is chosen to minimize effector functions (like ADCC or CDC), focusing the mechanism purely on ligand blockade.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.